Arch Pathol Lab Med. 2015 Mar;139(3):300-4. doi: 10.5858/arpa.2014-0190-ED.
Payment for cancer biomarker testing.
Allen TC1.
Author information
- 1From the Department of Pathology, University of Texas Medical Branch, Galveston.
"...although personalized cancer therapy is successfully tackling
biological, technical, and pharmacologic challenges, payment
is emerging as the challenge most difficult to
overcome, and the one that puts the ultimate success of
personalized cancer therapy at greatest risk."
No comments:
Post a Comment